I came across a publication that describes in silico modelling suggesting that the β-sheet of CTX interacts in a region between the collagen binding domain and catalytic domain of MMP2 (sorry to go all science nerdy folks), so a reasonable candidate for the target. Seems from another publication that 73% of gliomas are MMP2+ and level of expression is correlated with poor prognosis (so maybe higher % in recurrent?), so a nice target.
CHM Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)